Causal links among amyloid, tau, and neurodegeneration
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Amyloid-β pathology is associated with greater tau pathology and facilitates tau propagation from the medial temporal lobe to the neocortex, where tau is closely associated with local neurodegeneration. The degree of the involvement of amyloid-β versus existing tau pathology in tau propagation and neurodegeneration has not been fully elucidated in human studies. Careful quantification of these effects can inform the development and timing of therapeutic interventions. We conducted causal mediation analyses to investigate the relative contributions of amyloid-β and existing tau to tau propagation and neurodegeneration in two longitudinal studies of individuals without dementia: the Baltimore Longitudinal Study of Aging (N = 103, age range 57–96) and the Alzheimer’s Disease Neuroimaging Initiative (N = 122, age range 56–92). As proxies of neurodegeneration, we investigated cerebral blood flow, glucose metabolism, and regional volume. We first confirmed that amyloid-β moderates the association between tau in the entorhinal cortex and in the inferior temporal gyrus, a neocortical region exhibiting early tau pathology (amyloid group × entorhinal tau interaction term β = 0.488, standard error [SE] = 0.126, P < 0.001 in the Baltimore Longitudinal Study of Aging; β = 0.619, SE = 0.145, P < 0.001 in the Alzheimer’s Disease Neuroimaging Initiative). In causal mediation analyses accounting for this facilitating effect of amyloid, amyloid positivity had a statistically significant direct effect on inferior temporal tau as well as an indirect effect via entorhinal tau (average direct effect =0.47, P < 0.001 and average causal mediation effect =0.44, P = 0.0028 in Baltimore Longitudinal Study of Aging; average direct effect =0.43, P = 0.004 and average causal mediation effect =0.267, P = 0.0088 in Alzheimer’s Disease Neuroimaging Initiative). Entorhinal tau mediated up to 48% of the total effect of amyloid on inferior temporal tau. Higher inferior temporal tau was associated with lower colocalized cerebral blood flow, glucose metabolism, and regional volume, whereas amyloid had only an indirect effect on these measures via tau, implying tau as the primary driver of neurodegeneration (amyloid–cerebral blood flow average causal mediation effect =−0.28, P = 0.021 in Baltimore Longitudinal Study of Aging; amyloid–volume average causal mediation effect =−0.24, P < 0.001 in Alzheimer’s Disease Neuroimaging Initiative). Our findings suggest targeting amyloid or medial temporal lobe tau might slow down neocortical spread of tau and subsequent neurodegeneration, but a combination therapy may yield better outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Alzheimer's Disease Neuroimaging Initiative (ADNI)
Petersen, R. C., Aisen, P. S., Beckett, L. A., Donohue, M. C., Gamst, A. C., Harvey, D. J., Jack, C. R., Jagust, W. J., Shaw, L. M., Toga, A. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181cb3e25 · Cited by 2,572
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“(1) To what extent is neocortical tau accumulation driven by Aβ versus MTL tau pathology? As expected based on the visual assessment of the relationship between EC tau and ITG tau by amyloid status (Fig.”
Donanemab in Early Alzheimer’s Disease
Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100708 · Cited by 1,728 · cited 1×
“47 An amyloid intervention earlier in the disease course, combined with a tau-targeting therapy, might yield more pronounced effects on neocortical tau.”
Identification, Inference and Sensitivity Analysis for Causal Mediation Effects
Imai, K., Keele, L., & Yamamoto, T. (2010) · Statistical Science · doi:10.1214/10-sts321 · Cited by 1,628 · cited 1×
“44”
Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
Gómez‐Isla, T., Hollister, R., West, H., Mui, S., Growdon, J. H., Petersen, R. C., Parisi, J. E., & Hyman, B. T. (1997) · Annals of Neurology · doi:10.1002/ana.410410106 · Cited by 1,489
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease
Ossenkoppele, R., Schonhaut, D. R., Schöll, M., Lockhart, S. N., Ayakta, N., Baker, S. L., O’Neil, J. P., Janabi, M., Lazaris, A., Cantwell, A., et al. (2016) · Brain · doi:10.1093/brain/aww027 · Cited by 1,185
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“We used binary amyloid status based on fibrillar A β burden, but a measure of soluble A β could have been more appropriate given the evidence that soluble forms induce tau hyperphosphorylation 60 and may be more closely involved in neurodegeneration rather than fibrillar amyloid.”
Neuronal activity enhances tau propagation and tau pathology in vivo
Wu, J. W., Hussaini, S. A., Bastille, I. M., Rodriguez, G. A., Mrejeru, A., Rilett, K., Sanders, D. W., Cook, C., Fu, H., Boonen, R. A. C. M., et al. (2016) · Nature Neuroscience · doi:10.1038/nn.4328 · Cited by 820
Causal inference and the data-fusion problem
Bareinboim, E., & Pearl, J. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510507113 · Cited by 621
La Joie, R., Visani, A. V., Baker, S. L., Brown, J. A., Bourakova, V., Cha, J., Chaudhary, K., Edwards, L., Iaccarino, L., Janabi, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5732 · Cited by 612 · cited 1×
“8 Tau pathology is also associated locally with other markers of neurodegeneration, including lower cerebral blood flow (CBF), 9,10 glucose metabolism, 11,12 and volume.”
Jack, C. R., Twomey, C. K., Zinsmeister, A. R., Sharbrough, F. W., Petersen, R. C., & Cascino, G. D. (1989) · Radiology · doi:10.1148/radiology.172.2.2748838 · Cited by 592 · cited 1×
“30”
Interpretation and identification of causal mediation
Pearl, J. (2014) · Psychological Methods · doi:10.1037/a0036434 · Cited by 554 · cited 2×
“41 The average causal mediation effect (ACME; also known as the natural indirect effect) for the amyloid negative (A–) group, denoted ACME A– , is the expected difference in the outcome while amyloid status is fixed at A– and the mediator (tau) changes from the value attained or that would have…”
Longitudinal tau PET in ageing and Alzheimer’s disease
Jack, C. R., Wiste, H. J., Schwarz, C. G., Lowe, V. J., Senjem, M. L., Vemuri, P., Weigand, S. D., Therneau, T. M., Knopman, D. S., Gunter, J. L., et al. (2018) · Brain · doi:10.1093/brain/awy059 · Cited by 452
Neurons May Live for Decades with Neurofibrillary Tangles
Morsch, R., Simon, W., & Coleman, P. D. (1999) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199902000-00008 · Cited by 370
Neuritic pathology and dementia in alzheimer's disease
McKee, A. C., Kosik, K. S., & Kowall, N. W. (1991) · Annals of Neurology · doi:10.1002/ana.410300206 · Cited by 358 · cited 1×
“It is also possible that there are mechanisms by which cortical fibrillar amyloid deposition can influence MTL tau pathology; for example, amyloid pathology is associated with axonal dystrophy, 62 which might be a mechanism by which neocortical amyloid exerts retrograde effects.”
Doshi, J., Erus, G., Ou, Y., Resnick, S. M., Gur, R. C., Gur, R. E., Satterthwaite, T. D., Furth, S., & Davatzikos, C. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2015.11.073 · Cited by 309 · cited 1×
“We computed anatomical labels and regional brain volumes using Multi-atlas region Segmentation using Ensembles of registration algorithms and parameters, 28 and intracranial volume (ICV) was determined from intracranial masks computed using a deep learning approach.”
Self-citationJacobs, H. I. L., Hedden, T., Schultz, A. P., Sepulcre, J., Perea, R. D., Amariglio, R. E., Papp, K. V., Rentz, D. M., Sperling, R. A., & Johnson, K. A. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0070-z · Cited by 270
Reducing between scanner differences in multi-center PET studies
Joshi, A., Koeppe, R. A., & Fessler, J. A. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.057 · Cited by 247
Early stages of tau pathology and its associations with functional connectivity, atrophy and memory
Berron, D., Vogel, J. W., Insel, P. S., Pereira, J. B., Xie, L., Wisse, L. E. M., Yushkevich, P. A., Palmqvist, S., Mattsson-Carlgren, N., Stomrud, E., et al. (2021) · Brain · doi:10.1093/brain/awab114 · Cited by 240 · cited 1×
“We focus specifically on ITG for evaluating neocortical tau because it is an early neocortical region exhibiting tau pathology 18 and has often been used to measure tau pathology among individuals without dementia.”
Amyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease
Pooler, A. M., Polydoro, M., Maury, E. A., Nicholls, S. B., Reddy, S. M., Wegmann, S., William, C., Saqran, L., Cagsal-Getkin, O., Pitstick, R., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0199-x · Cited by 236
Sanchez, J. S., Becker, J. A., Jacobs, H. I. L., Hanseeuw, B. J., Jiang, S., Schultz, A. P., Properzi, M. J., Katz, S. R., Beiser, A., Satizabal, C. L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc0655 · Cited by 200 · cited 2×
“6,7 Once tau pathology spreads to the neocortex, it becomes closely linked with neurodegeneration.”
Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease
Iaccarino, L., Tammewar, G., Ayakta, N., Baker, S. L., Bejanin, A., Boxer, A. L., Gorno-Tempini, M. L., Janabi, M., Kramer, J. H., Lazaris, A., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2017.09.016 · Cited by 165
Fluorodeoxyglucose metabolism associated with tau‐amyloid interaction predicts memory decline
Hanseeuw, B. J., Betensky, R. A., Schultz, A. P., Papp, K. V., Mormino, E. C., Sepulcre, J., Bark, J. S., Cosio, D. M., LaPoint, M., Chhatwal, J. P., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24910 · Cited by 140 · cited 2×
“12,50 Our finding that tau pathology mediated the association of amyloid with volume in ADNI but not BLSA might be explained by differences in the composition of the samples: most ADNI participants included in our analyses had MCI, whereas most BLSA participants were cognitively normal.”
Predicting future rates of tau accumulation on PET
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Botha, H., Graff-Radford, J., Jones, D. T., Ferman, T. J., et al. (2020) · Brain · doi:10.1093/brain/awaa248 · Cited by 117
Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer’s disease
Strom, A., Iaccarino, L., Edwards, L., Lesman-Segev, O. H., Soleimani-Meigooni, D. N., Pham, J., Baker, S. L., Landau, S. M., Jagust, W. J., Miller, B. L., et al. (2022) · Brain · doi:10.1093/brain/awab294 · Cited by 91 · cited 1×
“8 Tau pathology is also associated locally with other markers of neurodegeneration, including lower cerebral blood flow (CBF), 9,10 glucose metabolism, 11,12 and volume.”
Cited by
Astrocyte biomarkers GFAP and YKL‐40 mediate early Alzheimer's disease progression
Pelkmans, W., Shekari, M., Brugulat‐Serrat, A., Sánchez‐Benavides, G., Minguillón, C., Fauria, K., Molinuevo, J. L., Grau‐Rivera, O., González Escalante, A., Kollmorgen, G., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13450 · Cited by 122
Veitch, D. P., Weiner, M. W., Miller, M., Aisen, P. S., Ashford, M. A., Beckett, L. A., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., et al. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13449 · Cited by 113
Boccalini, C., Ribaldi, F., Hristovska, I., Arnone, A., Peretti, D. E., Mu, L., Scheffler, M., Perani, D., Frisoni, G. B., & Garibotto, V. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13355 · Cited by 82
“3 Thus, T deposition initially local-izedinthemedialtemporallobes,subsequentlyspreadsstereotypically into the temporal, parietal, and frontal cortices in patients with AD.”
Background
Metadata
- Authors
- Bilgel, M., Wong, D. F., Moghekar, A. R., Ferrucci, L., Resnick, S. M., & Initiative, T. A. D. N.
- Venue
- Brain Communications
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-07-04
- Volume
- 4
- Issue
- 4
- Pages
- fcac193-fcac193
- ISSN
- 2632-1297 (ISSN-L)
- OpenAlex
- W4287378024
- Cited by
- 40
- References
- 27
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.